Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dr Reddy's Slumps In Q1 But Will Pressures Ease Soon?

Executive Summary

Dr. Reddy’s Laboratories (DRL) has reported a slump in profits for the first quarter, dented by a decline in volume growth and pricing pressure in the US as well as a loss of business in Venezuela. While the firm's long term story appears intact, resolution of compliance issues at its Indian sites and product flows in the US and other markets (DRL expects to participate in a Russian tender for rituximab) could lift investor sentiment significantly.


Related Content

Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2
Dr Reddy's Rituximab Build-Up And Going Beyond The Pill
Court Stays Controversial Indian Price Freeze
Dr. Reddy’s Pumps Complex Generics Play With Teva Deal
Venezuela Hits Dr. Reddy’s Profit, But Indicators Brighter
Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs


Related Companies